BioFocus DPI Extends Drug Discovery Collaboration with Lilly
News Feb 25, 2009
BioFocus DPI, the service division of Galapagos, has extended its drug discovery agreement with Eli Lilly and Company until end 2009. Under the terms of the agreement, BioFocus DPI will identify active compounds by screening of Lilly’s library compounds.
The agreement extension builds on the successful collaboration begun in March 2005. BioFocus DPI has been working with Lilly on discovering new compounds that target specific cellular signal transduction pathways. With this agreement, Lilly secures continued access to BioFocus DPI’s screening and biology expertise to identify new potential target compounds.
“We are pleased to extend this collaboration with Lilly into its fourth year,” said Dr. Chris Newton, Senior VP, BioFocus DPI. “It is satisfying to know that BioFocus DPI’s drug discovery research consistently meets the standards of large pharma companies, such as Lilly, and that we are successful in these long term collaborative relationships.”
This announcement is unrelated to the major osteoporosis alliance that Galapagos initiated with Lilly in December 2007, in which Galapagos’ drug discovery division will be responsible for the development of novel osteoporosis drug candidates potentially through to Phase IIa clinical Proof of Concept.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE